Leadership Change
Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline
Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change
Novo Nordisk’s Pipeline Cull Prompts Hopes of Strategic Shift
Novo Nordisk; pipeline cull; GLP-1/GIP co-agonist; obesity drugs; leadership change; strategic shift; semaglutide; Wegovy; R&D pipeline; market competition
Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges
Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations
Genentech’s Kristin Bittenbender Named BIO Board Chair Amid Industry Challenges
BIO; Genentech; Kristin Bittenbender; board chair; biotech industry; FDA; existential threats; leadership change; biotechnology policy
GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs
GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment
UnitedHealth Group CEO Andrew Witty Steps Down; Stephen Hemsley Returns as CEO
UnitedHealth Group; Andrew Witty; Stephen Hemsley; CEO transition; leadership change; personal reasons; financial guidance suspension; stock drop
Galapagos Reconsiders Company Split After Market Developments
Galapagos; company split; cell therapy; drug development; strategic review; leadership change; market conditions
Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout
Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company
Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer
Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research
Applied Therapeutics Undergoes Leadership Change Amid FDA Rejection and Investor Lawsuit
Applied Therapeutics, FDA rejection, investor lawsuit, leadership change, John H. Johnson, Les Funtleyder, Shoshana Shendelman